A Phase 2b clinical trial previously demonstrated that pembrolizumab in combination with the long-acting IL-7 cytokine molecule NT-I7 improved survival in microsatellite-stable colorectal and pancreatic cancer relative to historical controls (colorectal: mOS 13.2 months treatment vs. 10.8 months historical controls; pancreatic cancer: mOS 11.1 months treatment vs. 6.1 months historical controls) [230]. Here, IL7 is linked to pancreatic neoplasm.